Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Ludwig Kappos; Giancarlo Comi; Hillel Panitch; Joel Oger; Jack Antel; Paul Conlon; Lawrence Steinman; Alexander Rae-Grant; John Castaldo; Nancy Eckert; Joseph B. Guarnaccia; Pamela Mills; Gary Johnson; Peter A. Calabresi; Carlo Pozzilli; Stefano Bastianello; Elisabetta Giugni; Tatiana Witjas; Patrick Cozzone; Jean Pelletier; Dieter Pöhlau; Horst Przuntek; Volker Hoffmann; Christopher Bever; Eleanor Katz; Michel Clanet; Isabelle Berry; David Brassat; Irene Brunet; Gilles Edan; Pierre Duquette; Ernst Wilhelm Radue; Dagmar Schött; Carmen Lienert; Alice Taksaoui; M. Rodegher; M. Filippi; Alan Evans; Pierre Bourgouin; Alex Zijdenbos; Shawki Salem; Nicholas Ling; David Alleva; Eric Johnson; Amitabh Gaur; Paul Crowe; Xin Jun Liu

doi:10.1038/80525

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Ludwig Kappos, Giancarlo Comi, Hillel Panitch, Joel Oger, Jack Antel, Paul Conlon, Lawrence Steinman, Alexander Rae-Grant, John Castaldo, Nancy Eckert, Joseph B. Guarnaccia, Pamela Mills, Gary Johnson, Peter A. Calabresi, Carlo Pozzilli, Stefano Bastianello, Elisabetta Giugni, Tatiana Witjas, Patrick Cozzone, Jean PelletierDieter Pöhlau, Horst Przuntek, Volker Hoffmann, Christopher Bever, Eleanor Katz, Michel Clanet, Isabelle Berry, David Brassat, Irene Brunet, Gilles Edan, Pierre Duquette, Ernst Wilhelm Radue, Dagmar Schött, Carmen Lienert, Alice Taksaoui, M. Rodegher, M. Filippi, Alan Evans, Pierre Bourgouin, Alex Zijdenbos, Shawki Salem, Nicholas Ling, David Alleva, Eric Johnson, Amitabh Gaur, Paul Crowe, Xin Jun Liu

Research output: Contribution to journal › Article › peer-review

463 Scopus citations

Abstract

In this 'double-blind', randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing-remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.

Original language	English (US)
Pages (from-to)	1176-1182
Number of pages	7
Journal	Nature medicine
Volume	6
Issue number	10
DOIs	https://doi.org/10.1038/80525
State	Published - 2000
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/80525

Cite this

Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L., Rae-Grant, A., Castaldo, J., Eckert, N., Guarnaccia, J. B., Mills, P., Johnson, G., Calabresi, P. A., Pozzilli, C., Bastianello, S., Giugni, E., Witjas, T., Cozzone, P., ... Liu, X. J. (2000). Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature medicine, 6(10), 1176-1182. https://doi.org/10.1038/80525

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. / Kappos, Ludwig; Comi, Giancarlo; Panitch, Hillel et al.
In: Nature medicine, Vol. 6, No. 10, 2000, p. 1176-1182.

Research output: Contribution to journal › Article › peer-review

Kappos, L, Comi, G, Panitch, H, Oger, J, Antel, J, Conlon, P, Steinman, L, Rae-Grant, A, Castaldo, J, Eckert, N, Guarnaccia, JB, Mills, P, Johnson, G, Calabresi, PA, Pozzilli, C, Bastianello, S, Giugni, E, Witjas, T, Cozzone, P, Pelletier, J, Pöhlau, D, Przuntek, H, Hoffmann, V, Bever, C, Katz, E, Clanet, M, Berry, I, Brassat, D, Brunet, I, Edan, G, Duquette, P, Radue, EW, Schött, D, Lienert, C, Taksaoui, A, Rodegher, M, Filippi, M, Evans, A, Bourgouin, P, Zijdenbos, A, Salem, S, Ling, N, Alleva, D, Johnson, E, Gaur, A, Crowe, P & Liu, XJ 2000, 'Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial', Nature medicine, vol. 6, no. 10, pp. 1176-1182. https://doi.org/10.1038/80525

@article{f45dd3d3272c4b9a914131adee3066bd,

title = "Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial",

abstract = "In this 'double-blind', randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing-remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.",

author = "Ludwig Kappos and Giancarlo Comi and Hillel Panitch and Joel Oger and Jack Antel and Paul Conlon and Lawrence Steinman and Alexander Rae-Grant and John Castaldo and Nancy Eckert and Guarnaccia, {Joseph B.} and Pamela Mills and Gary Johnson and Calabresi, {Peter A.} and Carlo Pozzilli and Stefano Bastianello and Elisabetta Giugni and Tatiana Witjas and Patrick Cozzone and Jean Pelletier and Dieter P{\"o}hlau and Horst Przuntek and Volker Hoffmann and Christopher Bever and Eleanor Katz and Michel Clanet and Isabelle Berry and David Brassat and Irene Brunet and Gilles Edan and Pierre Duquette and Radue, {Ernst Wilhelm} and Dagmar Sch{\"o}tt and Carmen Lienert and Alice Taksaoui and M. Rodegher and M. Filippi and Alan Evans and Pierre Bourgouin and Alex Zijdenbos and Shawki Salem and Nicholas Ling and David Alleva and Eric Johnson and Amitabh Gaur and Paul Crowe and Liu, {Xin Jun}",

year = "2000",

doi = "10.1038/80525",

language = "English (US)",

volume = "6",

pages = "1176--1182",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "10",

}

TY - JOUR

T1 - Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

AU - Kappos, Ludwig

AU - Comi, Giancarlo

AU - Panitch, Hillel

AU - Oger, Joel

AU - Antel, Jack

AU - Conlon, Paul

AU - Steinman, Lawrence

AU - Rae-Grant, Alexander

AU - Castaldo, John

AU - Eckert, Nancy

AU - Guarnaccia, Joseph B.

AU - Mills, Pamela

AU - Johnson, Gary

AU - Calabresi, Peter A.

AU - Pozzilli, Carlo

AU - Bastianello, Stefano

AU - Giugni, Elisabetta

AU - Witjas, Tatiana

AU - Cozzone, Patrick

AU - Pelletier, Jean

AU - Pöhlau, Dieter

AU - Przuntek, Horst

AU - Hoffmann, Volker

AU - Bever, Christopher

AU - Katz, Eleanor

AU - Clanet, Michel

AU - Berry, Isabelle

AU - Brassat, David

AU - Brunet, Irene

AU - Edan, Gilles

AU - Duquette, Pierre

AU - Radue, Ernst Wilhelm

AU - Schött, Dagmar

AU - Lienert, Carmen

AU - Taksaoui, Alice

AU - Rodegher, M.

AU - Filippi, M.

AU - Evans, Alan

AU - Bourgouin, Pierre

AU - Zijdenbos, Alex

AU - Salem, Shawki

AU - Ling, Nicholas

AU - Alleva, David

AU - Johnson, Eric

AU - Gaur, Amitabh

AU - Crowe, Paul

AU - Liu, Xin Jun

PY - 2000

Y1 - 2000

N2 - In this 'double-blind', randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing-remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.

AB - In this 'double-blind', randomized, placebo-controlled phase II trial, we compared an altered peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on magnetic resonance imaging in relapsing-remitting multiple sclerosis. A safety board suspended the trial because of hypersensitivity reactions in 9% of the patients. There were no increases in either clinical relapses or in new enhancing lesions in any patient, even those with hypersensitivity reactions. Secondary analysis of those patients completing the study showed that the volume and number of enhancing lesions were reduced at a dose of 5 mg. There was also a regulatory type 2 T helper-cell response to altered peptide ligand that cross-reacted with the native peptide.

UR - http://www.scopus.com/inward/record.url?scp=0033791462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033791462&partnerID=8YFLogxK

U2 - 10.1038/80525

DO - 10.1038/80525

M3 - Article

C2 - 11017151

AN - SCOPUS:0033791462

SN - 1078-8956

VL - 6

SP - 1176

EP - 1182

JO - Nature medicine

JF - Nature medicine

IS - 10

ER -

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this